NCT04736329View on ClinicalTrials.gov

Telmisartan Versus Enalapril in Heart Failure With Reduced Ejection Fraction Patients With Moderately Impaired Kidney Functions

NACompletedINTERVENTIONAL
Enrollment

107

Participants

Timeline

Start Date

February 1, 2021

Primary Completion Date

July 30, 2022

Study Completion Date

October 31, 2022

Conditions
Heart Failure With Reduced Ejection FractionRenal Insufficiency
Interventions
DRUG

Telmisartan

Telmisartan (20 up to 80mg) for RAAS inhibition, as part of heart failure therapy.

Trial Locations (1)

11562

Kasralainy hospital, faculty of medicine, Cairo university, Cairo

All Listed Sponsors
lead

Cairo University

OTHER

NCT04736329 - Telmisartan Versus Enalapril in Heart Failure With Reduced Ejection Fraction Patients With Moderately Impaired Kidney Functions | Biotech Hunter | Biotech Hunter